等待开盘 07-01 09:30:00 美东时间
+2.410
+22.42%
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on ProMIS Neurosciences (NASDAQ:PMN) with a Overweight rating.
06-30 21:32
今日重点评级关注:Ascendiant Capital:维持IGC Pharma"买入"评级,目标价从5.25美元升至5.5美元;Ascendiant Capital:维持Lucid Diagnostics"买入"评级,目标价从9美元升至9.25美元
06-09 11:33
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.
06-08 23:37
ProMIS Neurosciences Inc. will participate in several June 2026 conferences to discuss its EpiSelect™ platform and lead Alzheimer's disease candidate, PMN310, which targets toxic amyloid-beta oligomers. The company plans to present at the Jefferies Global Healthcare Conference, Virtual Alzheimer’s R&D Day, H.C. Wainwright Neuro Perspectives Expert Summit, and BIO International Convention. ProMIS expects to report interim data from its PRECISE-AD ...
05-28 14:13
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.26) per share which beat the analyst consensus estimate of $(1.48) by 14.86 percent. This is a 76 percent increase over losses of $(5.25) per share from
05-12 18:57
ProMIS Neurosciences Inc. announced the completion of a PIPE financing up to $175 million, including warrants, to fund operations through 2027, supporting the Phase 1b PRECISE-AD trial for Alzheimer's disease (AD). The trial, fully enrolled with 144 participants, is on track for a blinded interim analysis in early Q3 2026 and top-line data in early 2027. The interim analysis will assess safety data, including ARIA incidence, and biomarker trends....
05-12 10:30
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(21.83) per share which missed the analyst consensus estimate of $(0.21) by 10295.24 percent. This is a 4266 percent decrease over losses of $(0.50) per
03-25 20:05
ProMIS Neurosciences, Inc. (NASDAQ:PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that it will
03-18 20:03